Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Acute coronary syndromes monitoring

Formulate a monitoring plan for a patient with ST-segment elevation acute coronary syndrome receiving fibrinolytics, aspirin, unfractionated heparin, intravenous nitroglycerin, intravenous (3-blockers followed by oral P-blockers, an angiotensin-converting enzyme inhibitor, and a statin. [Pg.83]

Devise a pharmacotherapy treatment and monitoring plan for a patient with non-ST-segment elevation acute coronary syndrome given patient-specific data. [Pg.83]

TABLE 5-5. Therapeutic Drug Monitoring for Adverse Effects of Pharmacotherapy for Acute Coronary Syndromes... [Pg.103]

Akkerhuis KM, Klootwijd PA, Lindeboom W et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events meta-analysis of three studies involving 995 patients. Eur Heart J 2001 22 1997. [Pg.310]

Specific leads may also be used in monitoring patients with acute coronary syndromes. [Pg.280]

The table below lists the best leads for monitoring challenging cardiac arrhythmias and special situations such as acute coronary syndromes. [Pg.280]

See other pages where Acute coronary syndromes monitoring is mentioned: [Pg.1]    [Pg.615]    [Pg.519]    [Pg.1438]    [Pg.120]    [Pg.141]    [Pg.67]    [Pg.460]    [Pg.215]    [Pg.191]   
See also in sourсe #XX -- [ Pg.313 , Pg.314 , Pg.314 ]



SEARCH



Acute coronary syndrome, monitoring patients with

Coronary syndromes

© 2024 chempedia.info